Ceragenins Prevent the Development of Murine Vaginal Infection Caused by <i>Gardnerella vaginalis</i>

<b>Background/Objectives:</b> Bacterial vaginosis (BV), an infection caused primarily by <i>Gardnerella vaginalis</i>, is the most prevalent vaginal infection. Although BV is often characterized by an asymptomatic course, it can lead to considerable health complications. Curr...

Full description

Saved in:
Bibliographic Details
Main Authors: Urszula Wnorowska (Author), Ewelina Piktel (Author), Tamara Daniluk (Author), Paulina Paprocka (Author), Paul B. Savage (Author), Bonita Durnaś (Author), Robert Bucki (Author)
Format: Book
Published: MDPI AG, 2024-10-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:<b>Background/Objectives:</b> Bacterial vaginosis (BV), an infection caused primarily by <i>Gardnerella vaginalis</i>, is the most prevalent vaginal infection. Although BV is often characterized by an asymptomatic course, it can lead to considerable health complications. Currently, BV therapy choices are limited, and available treatments are complicated by concerns about antibiotic resistance. Ceragenins, which together comprise an innovative class of low molecular-weight, cholic acid-based antibacterial agents, have emerged as potential alternatives to conventional treatments. <b>Methods:</b> This study investigates (i) the antibacterial activity of ceragenins against <i>G. vaginalis</i> in in vitro experimental settings at varied pH, and (ii) the effectiveness and anti-inflammatory properties of CSA-13 in a <i>G. vaginalis</i>-induced bacterial vaginosis animal model. <b>Results and Conclusions:</b> We demonstrate that ceragenins, particularly CSA-13, maintain their antibacterial efficacy throughout pH range of 4.5-7, with the highest activity observed at neutral pH (7.0). Additionally, in an animal model, beneficial effects of ceragenins are attributed to anti-inflammatory properties of these compounds, making these compounds promising agents as potential new treatment options against <i>G. vaginalis</i>-associated vaginal infections.
Item Description:10.3390/ph17111445
1424-8247